Subscribe

Shitanshu Uppal

SHAPE Trial: Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer

Simple hysterectomy is not inferior to radical hysterectomy in terms of the 3-year incidence of pelvic recurrence and presents a lower risk of urinary complications.

PAOLA-1: Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

The addition of maintenance olaparib with bevacizumab significantly improves progression-free survival, especially in patients with HRD-positive tumors, including those without a BRCA mutation.

GOG 209: Carboplatin and Paclitaxel for Advanced Endometrial Cancer

The TC regimen demonstrated noninferiority to TAP in terms of OS and PFS while offering a better toxicity profile, making it a suitable first-line treatment for advanced endometrial cancer

KEYNOTE-826: Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Pembrolizumab significantly improves PFS and OS in PD-L1–positive persistent, recurrent, or metastatic cervical cancer patients when added to standard chemotherapy, with or without bevacizumab, maintaining a manageable safety profile.

GYOEDU One-on-One Coaching and Mentorship

GYOEDU's unique program blends mentorship with executive coaching

Navigation Help

Welcome

Sarcoma Trials

List of key sarcoma trials

GOG 277: Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma

Adjuvant chemotherapy with gemcitabine plus docetaxel followed by doxorubicin does not show superior outcomes compared to observation for high-grade uterine leiomyosarcoma.

GeDDiS Trial: Gemcitabine and docetaxel versus doxorubicin as first-line treatment sarcomas

Doxorubicin remains the standard first-line treatment for most patients with advanced soft-tissue sarcoma, as gemcitabine and docetaxel did not demonstrate superiority in survival outcomes

Trabectedin